Hologic Inc.

Company Snapshot

Founded: 1985
Entity Type: Public
Employees: 7,070
Region: U.S.
Revenue: $4,100.5 Millions
Revenue Year: 2025
Headquarter: Marlborough, Massachusetts, U.S.
Key Geographics: U.S., Europe, Asia-Pacific, Rest of World
Corporate Address: 250 Campus Drive, Marlborough, Massachusetts 01752 U.S. Tel. +1-508-263-2900 www.hologic.com

Company Overview

Hologic is a medical technology company offering diagnostics and breast, skeletal, and gynecological surgical health products. The company operates in four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. Its diagnostics products include its molecular diagnostic assays. It has a presence in over 15 countries and 7,063 employees globally. Diagenode, a Hologic company, provides devices, kits, reagents, antibodies, and services for epigenetics research and diagnostic assays. The company's product portfolio includes Bioruptor shearing and IP-Star automation instruments, reagent kits and antibodies to streamline DNA methylation, chromatin immunoprecipitation (ChIP) and ChIP-seq workflows. The company also offers the Megaruptor shearing system for long fragment generation in sequencing and epigenetics assay services.

Financial Highlights (FY 2025)

Net Revenue: ***
Total Current Liabilities: ***
Total Current Assets: ***
R&D expenses: ***
Operating Income: ***

This information is available for BCC Research members only.

Hologic Inc. In Reports

Molecular Diagnostics: Technologies and Global Markets

According to our research analyst the molecular diagnostics market includes global revenue ($ Million) for the base year 2024 and estimated data for the forecast period 2025 through 2030.

Global MedTech Healthcare IT Industry Competitive Landscape

BCC Research Market Analyst says global market for medical devices was valued at $810.4 billion in 2024 and is projected to reach $1.4 trillion by the end of 2030.

Global Mammography Equipment Markets

BCC Research Market Analyst says global market for mammography equipment is projected to grow from $3.1 billion in 2025 to reach $4 billion by the end of 2030, at a CAGR of 5.2%.

Company's Business Segments

  • Diagnostics : Cytology & Perinatal, Molecular Diagnostics, Blood Screening
  • Breast Health : Breast Imaging, Interventional Breast Solutions
  • GYN Surgical : Myosure Hysteroscopic Tissue Removal System, Novasure Endometrial Ablation System, Fluent Fluid Management System, Acessa Provu Laparoscopic Radiofrequency Ablation System, Coolseal Vessel Sealing Portfolio, Justright Surgical Stapler
  • Skeletal Health : Horizon DXA, Fluoroscan Insight FD mini C-arm

Applications/End User Industries

  • Molecular Diagnostics
  • Cytology
  • Tests
  • Collection Devices
  • Screening Technologies
AI Sentiment